Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The market dynamics of antibiotics are profoundly motivated by the global burden of infectious sicknesses, the continued risk of antimicrobial resistance, and the constant want for powerful remedies against bacterial infections. One of the number one drivers is the continual prevalence of bacterial infections internationally, starting from commonplace breathing infections to greater severe situations. Technological advancements play a pivotal role in shaping the antibiotics market dynamics. Innovations in drug discovery and improvement contribute to the advent of the latest antibiotic lessons with stepped-forward efficacy and decreased resistance capacity. The capacity to lay out antibiotics that focus on bacterial mechanisms enhances treatment options and affects market traits toward greater specific and targeted antimicrobial cures.
Regulatory concerns drastically affect the antibiotics market dynamics. Stringent guidelines governing the approval, manufacturing, and use of antibiotics ensure the protection and effectiveness of these critical medications. Global financial elements contribute to the antibiotics market dynamics by influencing the affordability and accessibility of those medicines. Economic prosperity may result in elevated healthcare spending, fostering investments in antibiotic studies and improvement. The presence of diverse pharmaceutical companies influences competition within the antibiotics marketers. Factors including drug efficacy, safety profiles, spectrum of activity, and market percentage contribute to the location of organizations within the market.
Research collaborations and scientific studies are vital for advancing antibiotic technology and addressing evolving bacterial resistance styles. Participation in medical studies enhances the understanding of bacterial biology, resistance mechanisms, and remedy outcomes. The rise of antimicrobial resistance and the want for novel antibiotic stewardship applications additionally influence the antibiotics market. Public awareness and education projects about antibiotic resistance and the prudent use of antibiotics make contributions to market increase. The market dynamics of antibiotics are also influenced by evolving options for mixture healing procedures and opportunity remedy modalities. As bacterial resistance challenges persist, there may be a trend toward exploring combination antibiotic treatment plans and opportunity techniques, such as phage remedies and immunotherapies.
Antibiotics Market Highlights:
Global Antibiotics Market Overview
Antibiotics Market Size was valued at USD 44.33 Billion in 2023. The Global Antibiotics industry is projected to grow from USD 46.43 Billion in 2024 to USD 67.66 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.82% during the forecast period (2024 - 2032).
Supportive government legislations, such as the implementation of the Generating Antibiotics Incentives Now (GAIN) Act in the US, are expected to accelerate the drug approval process in the antibiotics market.
GAIN Act facilitates the development of therapies against antibiotic-resistant pathogens. Thus, by this act, there is a rise in antibiotic approval in the US, with an average yearly approval rate more than double from 2000-2012 (0.8 approvals per year) to 2013-present (1.8 approvals per year). This creates a lucrative opportunity for the companies to enter the antibiotics market, thus fueling the market growth.
Market Influencers
An increasing number of antibiotics in the clinical development stage. In June 2019, approximately 42 new antibiotics with the ability to treat severe bacterial infections were in the clinical development stage. As a result, increasing the number of antibiotics would drive the demand for the antibiotics market.
Market Drivers
-
Major companies undertook increasing efforts for the development of advanced antibiotics. According to the data published by the Pew Charitable Trust, in March 2016, clinical research was conducted for approximately 37 drug molecules within the US market. Majority of these molecules are in phase II clinical trials and are anticipated to launch in the near future, thus accelerating the growth of antibiotics market
-
Increasing approval of antibiotic drugs. In 2018, about 59 antibiotic drugs such as xospata, firdapse, and asparlas were approved by the US Food and Drug Administration (FDA).
-
The rise in the incidence of chronic and infectious diseases. There has been an increase in infectious disease rates. For instance, more than 17 million people were affected by contagious diseases globally.
-
Growing investment opportunities by biotech companies in research & development. As of June 2019, approximately 42 new antibiotics with the potential to treat severe bacterial infections are in clinical development
-
Development of generic drugs
Market Restraints
- Increasing antibiotic-resistant infections. In the US, every year, approximately 2 million people are infected with antibiotic-resistant bacteria, and at least 23,000 people die as a result of this.
- Rise in drug approval costs
Antibiotics Market Segmentation
Antibiotics Drug class Outlook
-
Cephalosporins: They are class of β-lactam antibiotics originally derived from Acremonium and are effective against a wide range of bacteria. They kill bacteria and have similar functions to that of penicillin.
-
Penicillin: Penicillin is used to treat bacterial infections. It is primarily used for the treatment of various diseases such as pneumonia, meningitis, endocarditis, and others.
-
Fluoroquinolones: Fluoroquinolones are used to treat respiratory and urinary tract infections (UTIs).
-
Macrolides: Macrolide antibiotics are effective in treating bacterial infections such as ear, nose, and throat infections, chest infections, skin infections, and mouth and dental infections.
-
Carbapenem: Fastest-growing segment. Growing incidence of UTIs pneumonia and bloodstream infections are expected to increase the usage of carbapenems class of antibiotics. In 2016, the consumption of carbapenems in Europe was approximately 0.05 defined daily doses (DDD) per 1,000 people per day.
-
Aminoglycosides: Aminoglycosides are a class of antibiotics that are used mainly in the treatment of aerobic gram-negative bacilli infections.
-
Sulfonamides: Contains sulfonamide chemical group. This class of antibiotics is used in diabetes and pain relief.
-
Others: Others include tetracyclines, monoclonal antibodies, imidazoles, and lincosamides.
Antibiotics Drug Spectrum of Activity Outlook
-
Broad-spectrum Antibiotic: Largest segment. Broad-Spectrum antibiotics act against a wide range of diseases, which in turn helps to fight against antimicrobial resistance, thus driving the growth of this segment. Examples include aminoglycosides, cephalosporins, and quinolones.
-
Narrow-spectrum Antibiotic: Narrow-spectrum antibiotics are active against selected types of bacteria. Examples include macrolides and vancomycin.
Antibiotics Drug Drug Origin Outlook
-
Natural: Derived from natural sources such as plant extracts and essential oils that have antibiotic properties.
-
Semi-synthetic: Fastest-growing segment. Semi-synthetic antibiotics are the derivatives of natural antibiotics with somewhat different but useful characteristics. They can act against bacteria that are resistant to the original compound, have a broad-spectrum of activity, and cause fewer side-effects. An example of semisynthetic includes ampicillin drug.
-
Synthetic: Related to natural antibiotics. It includes the quinolone class of antibiotics.
Antibiotics Drug End-User Outlook
-
Hospitals & Clinics: The largest segment, a majority of treatment and procedures are carried out in hospitals. In 2016, the average consumption of antibiotics for systemic use in hospitals was 2.1 defined daily doses (DDD) per 1,000 people per day.
-
Research Organizations: They encourage the research & development of new antimicrobial drugs and diagnostics, thus would drive the growth of the antibiotics market. Global Antibiotic Research & Development Partnership address global public health needs by delivering and developing new or improved antibiotic treatments.
-
Others: Others include academic institutes, nursing homes, and emergency care centers.
Antibiotics Drug Region Outlook
-
Americas: The largest regional market. Rising growth in the pharmaceutical sector, increasing adoption of antibiotics, are the significant factors that would drive the growth of the antibiotics market in this region.
-
Europe: Rising consumption of antibiotics, high prevalence of infectious diseases, increase in usage of generic medicines. These factors are anticipated to drive the growth of the antibiotics market in this region.
-
Asia-Pacific: The fastest-growing regional market in antibiotics owing to the rising consumption of antibiotics, an increase in the sale of over the counter (OTC) drugs, and the easy availability of drugs.
-
Middle East & Africa: Increasing healthcare expenditure and rising consumption of antibiotics would drive the demand for the antibiotics market in this region.
Key Players
- Pfizer Inc. (US)
- Johnson & Johnson Services, Inc. (US)
- Abbott Laboratories (US)
- GlaxoSmithKline PLC (UK)
- Sanofi (France)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Bristol-Myers Squibb Company (US)
- Eli Lilly and Company (US)
- Astellas Pharma Inc. (Japan)
- Merck & Co., Inc. (US)
- F. Hoffmann-La Roche Ltd (Switzerland)
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
